Efavirenz

Treatment of HIV Infection

Efavirenz is prescribed to manage human immunodeficiency virus type 1 (HIV-1) infection. It belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). This medication is used for:

• Combination Therapy: Efavirenz is not used alone. It must be taken with other antiretroviral medications to effectively control the virus and prevent the development of drug resistance.
• Adult and Pediatric Use: It is used in adults and children who meet specific weight requirements determined by a healthcare provider.

Goals of Treatment

The primary objectives of using efavirenz as part of a treatment regimen include:

• Reducing the amount of HIV in the blood, often referred to as the viral load.
• Increasing the count of CD4 cells, which are white blood cells that help the immune system fight off infections.
• Lowering the risk of developing complications related to HIV, such as opportunistic infections.

It is important to note that efavirenz is not a cure for HIV or acquired immunodeficiency syndrome (AIDS). While the medication helps manage the condition and supports immune function, the virus remains in the body.

Mechanism of Action

Efavirenz belongs to a class of medications known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by interfering with the life cycle of the human immunodeficiency virus (HIV).

Blocking Viral Replication

To make copies of itself, HIV uses an enzyme called reverse transcriptase. This enzyme allows the virus to convert its genetic material (RNA) into DNA so it can integrate into human cells. Efavirenz binds directly to this enzyme and blocks its activity. By stopping this process, the medication:

• Prevents the virus from multiplying and infecting new cells.
• Decreases the total amount of HIV in the blood, often called the viral load.
• Helps the immune system function better by protecting CD4 (T) cells.

Specific Targets

Efavirenz is specifically active against HIV-1, the most common strain of the virus. It does not work against HIV-2. While efavirenz helps manage the infection and reduces the risk of complications, it is not a cure for HIV or AIDS. It must be used in combination with other antiviral medications to be effective and to prevent the virus from developing resistance.

Common Side Effects

Many people taking efavirenz experience mild to moderate side effects, particularly when first starting the medication. These may include:

• Dizziness or lightheadedness
• Headache
• Difficulty sleeping or unusual dreams
• Drowsiness or trouble concentrating
• Nausea, vomiting, or diarrhea
• Mild skin rash
• Fatigue

Serious Side Effects

While less common, some side effects require immediate medical attention. Contact a healthcare provider right away if you experience:

• Mental health changes: Severe depression, anxiety, aggression, hallucinations, or thoughts of hurting yourself or others.
• Severe skin reactions: A rash accompanied by fever, blistering, mouth sores, or swelling of the face and tongue.
• Liver problems: Yellowing of the skin or eyes (jaundice), dark-colored urine, pain in the upper right side of the stomach, or loss of appetite.
• Neurological issues: Seizures or severe dizziness that interferes with daily activities.
• Changes in body fat: Redistribution of body fat, such as increased fat in the upper back, neck, or trunk, and loss of fat from the arms and legs.

Nervous system symptoms like dizziness and vivid dreams often occur during the first few days of treatment and may improve after a few weeks. Taking the medication on an empty stomach at bedtime may help reduce these effects.

Psychiatric and Nervous System Effects

Efavirenz is associated with serious psychiatric symptoms, including severe depression, suicidal thoughts or attempts, aggressive behavior, and paranoid or manic reactions. Nervous system symptoms are also common, such as dizziness, insomnia, impaired concentration, and abnormal dreams. These symptoms typically begin within the first few days of treatment and often resolve after several weeks, though they may persist in some cases.

Liver Health and Monitoring

Liver toxicity has been reported in patients using efavirenz. Healthcare providers usually monitor liver enzymes before and during treatment, especially in individuals with a history of hepatitis B or C infection or other liver diseases.

Pregnancy and Fetal Risk

Efavirenz may cause fetal harm, particularly neural tube defects, if taken during the first trimester of pregnancy. Pregnancy testing is typically performed before starting the medication, and effective contraception is recommended during treatment and for a period after the last dose.

Skin Reactions

While mild to moderate rashes are common, severe and life-threatening skin reactions like Stevens-Johnson syndrome can occur. If a severe rash develops, or if a rash is accompanied by fever or blistering, the medication is usually discontinued.

Drug Interactions

Efavirenz interacts with many other medications, including certain heart medicines, blood thinners, and herbal supplements like St. John's wort. These interactions can cause serious side effects or prevent the medications from working correctly.

Other Precautions

• Immune Reconstitution Syndrome: A condition where the immune system reacts strongly to previous infections as it recovers.
• Seizures: Caution is advised for individuals with a history of seizures, as convulsions have been observed.
• Fat Redistribution: Changes in body fat, such as gain in the trunk or loss in the limbs, may occur.
• QT Prolongation: Efavirenz may affect the heart's electrical rhythm, which can be serious if combined with other medications that have similar effects.

Pregnancy

Efavirenz may cause birth defects if taken during the first trimester of pregnancy. Because of this risk, healthcare providers typically require a pregnancy test before starting treatment. People who can become pregnant should follow these precautions:

• Use effective birth control during treatment and for at least 12 weeks after the last dose.
• Use a barrier method of contraception in addition to hormonal contraceptives, as efavirenz may reduce the effectiveness of hormonal birth control.
• Notify a healthcare provider immediately if pregnancy is suspected or confirmed while taking this medication.

Breastfeeding

Health experts generally recommend that individuals with HIV do not breastfeed. This is because the virus can be passed to the baby through breast milk. Additionally, efavirenz has been shown to pass into breast milk, and its effects on a nursing infant are not fully known.

Available Forms

Efavirenz is manufactured in the following oral dosage forms:

• Oral Capsules: These are intended to be swallowed whole.
• Oral Tablets: These are intended to be swallowed whole.

In addition to being available as a single-ingredient medication, efavirenz is also found in fixed-dose combination tablets. These products combine efavirenz with other antiretroviral medicines into a single pill to simplify treatment for HIV-1 infection.

FDA Approval and Indications

Efavirenz was first approved by the U.S. Food and Drug Administration (FDA) in 1998. It is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients. Regulatory guidelines specify that efavirenz must always be used in combination with other antiretroviral agents to prevent the development of drug resistance.

Safety Warnings and Regulatory Status

The FDA-approved labeling for efavirenz includes several significant warnings regarding its safety profile:

• Psychiatric Symptoms: Serious psychiatric adverse experiences have been reported, including severe depression, suicidal ideation, and non-fatal suicide attempts.
• Nervous System Symptoms: Patients frequently experience dizziness, insomnia, and impaired concentration, particularly when starting therapy.
• Hepatotoxicity: There are warnings regarding potential liver damage, and monitoring of liver enzymes is recommended for patients with known or suspected hepatitis B or C.
• Embryo-Fetal Toxicity: Efavirenz may cause fetal harm when administered during the first trimester of pregnancy, and pregnancy testing is recommended for individuals of childbearing potential before starting treatment.

There is currently no Risk Evaluation and Mitigation Strategy (REMS) program required for efavirenz. It is available as a generic medication in multiple formulations, including oral capsules and tablets.

Risks of Stopping Treatment

Efavirenz is not associated with physical withdrawal symptoms like those seen with some other types of medications. However, stopping the medication abruptly or skipping doses can lead to serious complications in managing HIV infection. When the medication is not taken consistently, the amount of virus in the blood can increase rapidly.

Drug Resistance

The most significant risk of stopping efavirenz is the development of drug resistance. If the virus is allowed to multiply while the drug is still present in low levels in the body, it can mutate. This mutation may make the virus resistant to efavirenz and other similar antiretroviral drugs, which can make the infection much harder to treat in the future.

Importance of Consistency

To maintain the effectiveness of the treatment and prevent the virus from becoming resistant, it is important to follow these guidelines:

• Take the medication exactly as prescribed by a healthcare provider.
• Avoid skipping doses, as even short interruptions can increase the risk of treatment failure.
• Consult a doctor before stopping the medication for any reason, including side effects or other illnesses.
• Ensure a steady supply of medication is available to avoid accidentally running out.